Research Paper Volume 12, Issue 7 pp 5792—5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Figure 5. Overall survival and disease free survival according to cytogenetics. (A) Overall survival in AML patients with complex cytogenetics compared to others. (B) Disease free survival in AML patients with complex cytogenetics compared to others. (C) Overall survival in AML patients with abnormalities in -5/5q- and/or -7/7q- chromosomal deletions compared to others. (D) Disease free survival in AML patients with abnormalities in -5/5q- and/or -7/7q- chromosomal deletions compared to others. (E) Overall survival in AML patients with monosomal karyotype compared to others. (F) Disease free survival in AML patients with monosomal karyotype compared to others.